In Brief: Centeon/Medarex
Executive Summary
Centeon/Medarex: Companies will jointly develop MDX-33, a humanized monoclonal antibody for the treatment of autoimmune hematological disorders. Centeon will finance product development through Phase II trials up to $20 mil., as well as Phase III trials, regulatory approvals and launch costs. Centeon will pay Medarex $1 mil. for technology access, nearly $1 mil. for R&D funding for manufacturing improvements, and $10 mil. for achieving specific milestones. Centeon, a Rhone-Poulenc Rorer and Hoechst AG joint venture, will have exclusive marketing rights to MDX-33; Medarex will receive royalties...